TRACON Pharmaceuticals, Inc. (TCON)

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 944
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 369
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON)

Berichtdoor alles kan beter » 05 Apr 2018 12:19

ah ok, thx!
(jammer, een overname zou mooi geweest zijn)
Just when you think you've hit rock bottom, someone will hand you a shovel.



Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 944
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 369
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON)

Berichtdoor alles kan beter » 04 Mei 2018 14:47

PATRICIA L.
BITAR
NOTIFIED THAT RESIGNING AS CO'S CFO, EFFECTIVE JUNE 15, 2018-
SEC FILING
Just when you think you've hit rock bottom, someone will hand you a shovel.

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 944
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 369
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON)

Berichtdoor alles kan beter » 11 Mei 2018 08:56

TRACON PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO
27.4
MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS
Just when you think you've hit rock bottom, someone will hand you a shovel.

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 944
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 369
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON)

Berichtdoor alles kan beter » 25 Mei 2018 08:41

TRACON Pharmaceuticals (TCON) has a couple of near-term catalysts to keep an eye on.
-- Completion of the dose escalation portion of a phase 1/2 trial of TRC253 in patients with prostate cancer is expected in mid-2018. -- Announcement of top-line data from the randomized Phase 2 TRAXAR trial of TRC105 in combination with Inlyta for patients with advanced or metastatic renal cell carcinoma is expected in the second half of 2018. -- Announcement of the results of the interim analysis from the Phase 3 pivotal TAPPAS trial of TRC105 in angiosarcoma is expected in the second half of 2018. -- Presentation of data from the Phase 1b trial of TRC105 in combination with Opdivo in patients with non-small cell lung cancer is expected in the second half of 2018.
Just when you think you've hit rock bottom, someone will hand you a shovel.

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 944
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 369
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON)

Berichtdoor alles kan beter » 15 Jun 2018 15:59

SAN DIEGO, June 13, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that positive preclinical data from TRC105, TRACON’s endoglin antibody, in combination with a PD-1 antibody, were discussed in an oral presentation at the 2018 International Cancer Microenvironment Society meeting.
Dr. Mark Schoonderwoerd of Leiden University presented data from multiple murine models assessing the activity of TRC105 in combination with a PD-1 antibody. The individual antibodies as well as the combination were studied in two separate models. In the first, immunocompetent mice were implanted with a syngeneic colorectal cancer subcutaneously to mimic metastatic colorectal cancer. In the second, immunocompetent mice were implanted orthotopically to mimic advanced colorectal cancer.
In both models, treatment with either TRC105 or a PD-1 antibody alone decreased tumor volume compared to IgG control antibody to a similar degree. However, combined treatment with TRC105 and the PD-1 antibody significantly reduced tumor volume compared to treatment with TRC105 or PD-1 treatment alone.

Treatment with either TRC105 or a PD-1 antibody improved survival to a similar degree compared to control antibody. However, survival was significantly improved with combination treatment versus the individual therapies, with long-term survival demonstrated in 30% to 60% of animals. Combination treatment also increased tumor specific T cells, indicating stimulation of an immune response.

The activity of TRC105 given as a single agent or combined with a PD-1 antibody was diminished following CD8+ T cell depletion, indicating that TRC105 activity was mediated through an immunologic mechanism.
In a separately reported third preclinical study, an endoglin antibody specific for mouse endoglin that mimics TRC105 activity in mice, M1043, was studied in a chemically induced colorectal cancer model of early-stage colorectal cancer.
Combined treatment with M1043 and a PD-1 antibody significantly reduced tumor volume compared to treatment with M1043 or PD-1 treatment alone. Combination treatment also significantly reduced the number of tumors that formed in response to the chemically induced carcinogenesis.
TRC105 is currently being studied in the ongoing pivotal randomized Phase 3 TAPPAS trial in angiosarcoma (NCT02979899), the randomized Phase 2 TRAXAR trial in renal cell carcinoma (NCT01806064), a Phase 1/2 trial in patients with hepatocellular carcinoma (NCT02560779), and a Phase 1 trial studying the combination of TRC105 and nivolumab (Opdivo) in patients with non-small cell lung cancer (NCT03181308).
About TRACON
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at http://www.traconpharma.com.
Jojo liked last!
Just when you think you've hit rock bottom, someone will hand you a shovel.

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 944
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 369
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON)

Berichtdoor alles kan beter » 15 Jun 2018 16:00

rondgaan brengt op : momenteel +6..
Just when you think you've hit rock bottom, someone will hand you a shovel.

Gebruikersavatar
Jojo
Premiummember
Premiummember
Berichten: 498
Lid geworden op: 19 Dec 2013 15:26
waarderingen: 151
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON)

Berichtdoor Jojo » 15 Jun 2018 19:10

alles kan beter schreef:rondgaan brengt op : momenteel +6..


Ondertussen 18 %
Gilead Ageas Genmab ASMI Sphere3D GSK CFEB LBrands Melexis Umicore Euronav Nordex Solvay Grandvision Biocartis AXA Befimmo AHDelh ABInbev TCON ACIU BMW RioTinto

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 944
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 369
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON)

Berichtdoor alles kan beter » 16 Jun 2018 08:01

Jojo schreef:
alles kan beter schreef:rondgaan brengt op : momenteel +6..


Ondertussen 18 %

serieuze bokkesprongen gisteren. helaas de sprong gemist :cry: :oops:
Just when you think you've hit rock bottom, someone will hand you a shovel.

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 944
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 369
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON)

Berichtdoor alles kan beter » 09 Aug 2018 06:07

..
Expected Upcoming Milestones
Announcement of top-line data from the randomized Phase 2 TRAXAR trial of TRC105 in combination with Inlyta for patients with advanced or metastatic renal cell carcinoma is expected prior to the end of 2018.

Announcement of data from the Phase 1b trial of TRC105 in combination with Opdivo in patients with non-small cell lung cancer is expected prior to the end of 2018.

Announcement of the results of the interim analysis from the Phase 3 pivotal TAPPAS trial of TRC105 in angiosarcoma is expected in Q1 2019.
Second Quarter 2018 Financial Results
Cash, cash equivalents and short-term investments were $53.4 million at June 30, 2018, compared to $34.5 million at December 31, 2017. We expect our current cash, cash equivalents and short-term investments to fund operations into Q4 2019.

Research and development expenses for the second quarter of 2018 were $8.1 million compared to $4.9 million for the second quarter of 2017. The increase was primarily attributable to increased TRC105 drug manufacturing activities in the second quarter of 2018 as compared to the 2017 period.

General and administrative expenses for the second quarter of 2018 were $1.6 million compared to $2.1 million for the second quarter of 2017.

Net loss for the second quarter of 2018 was $9.8 million compared to $6.6 million for the second quarter of 2017.

….
Just when you think you've hit rock bottom, someone will hand you a shovel.

Lampi
Forum actieveling
Forum actieveling
Berichten: 493
Lid geworden op: 21 Jun 2017 19:29
waarderingen: 160
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON)

Berichtdoor Lampi » 09 Aug 2018 14:32

wou wat meer inkijken in dit aandeel, maar de website is niet toegankleijk? nog iemand dit probleem?